4SCAR-T Therapy Post CD19-targeted Immunotherapy

Summary

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells (4SCAR-T) targeting CD19-negative B-ALL that express alternative surface antigens such as CD22, CD10, CD20, CD38, and CD123, as many patients relapse after anti-CD19 immunotherapy. Clinical response and optiminzation of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.

Timeline

Start

2026-06-01

Primary completion

2029-12-31

Completion

2030-12-31

Drugs

Indications

No indication recorded.